309 related articles for article (PubMed ID: 7904934)
1. Arrhythmia control by prolonging repolarization: the concept and its potential therapeutic impact.
Singh BN
Eur Heart J; 1993 Nov; 14 Suppl H():14-23. PubMed ID: 7904934
[TBL] [Abstract][Full Text] [Related]
2. Controlling cardiac arrhythmias by lengthening repolarization: historical overview.
Singh BN
Am J Cardiol; 1993 Nov; 72(16):18F-24F. PubMed ID: 8237826
[TBL] [Abstract][Full Text] [Related]
3. The coming of age of the class III antiarrhythmic principle: retrospective and future trends.
Singh BN
Am J Cardiol; 1996 Aug; 78(4A):17-27. PubMed ID: 8780325
[TBL] [Abstract][Full Text] [Related]
4. Current antiarrhythmic drugs: an overview of mechanisms of action and potential clinical utility.
Singh BN
J Cardiovasc Electrophysiol; 1999 Feb; 10(2):283-301. PubMed ID: 10090235
[TBL] [Abstract][Full Text] [Related]
5. Choice and chance in drug therapy of cardiac arrhythmias: technique versus drug-specific responses in evaluation of efficacy.
Singh BN
Am J Cardiol; 1993 Nov; 72(16):114F-124F. PubMed ID: 8237824
[TBL] [Abstract][Full Text] [Related]
6. Electrophysiologic basis for the antiarrhythmic actions of sotalol and comparison with other agents.
Singh BN
Am J Cardiol; 1993 Aug; 72(4):8A-18A. PubMed ID: 8346731
[TBL] [Abstract][Full Text] [Related]
7. Hemodynamic effects of antiarrhythmic compounds: intrinsic effects and autonomic modulation.
Hoffmeister HM; Beyer ME; Seipel L
Am J Cardiol; 1997 Oct; 80(8A):24G-30G. PubMed ID: 9354409
[TBL] [Abstract][Full Text] [Related]
8. Expanding clinical role of unique class III antiarrhythmic effects of sotalol.
Singh BN
Am J Cardiol; 1990 Jan; 65(2):84A-88A. PubMed ID: 2403738
[TBL] [Abstract][Full Text] [Related]
9. From first class to third class: recent upheaval in antiarrhythmic therapy--lessons from clinical trials.
Lazzara R
Am J Cardiol; 1996 Aug; 78(4A):28-33. PubMed ID: 8780326
[TBL] [Abstract][Full Text] [Related]
10. Pharmacodynamic, pharmacokinetic and antiarrhythmic properties of d-sotalol, the dextro-isomer of sotalol.
Advani SV; Singh BN
Drugs; 1995 May; 49(5):664-79. PubMed ID: 7601009
[TBL] [Abstract][Full Text] [Related]
11. Electrophysiologic properties of sotalol and d-sotalol. A current view.
Touboul P
Eur Heart J; 1993 Nov; 14 Suppl H():24-9. PubMed ID: 7904935
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetic and pharmacodynamic profiles of d-sotalol and d,l-sotalol.
Funck-Brentano C
Eur Heart J; 1993 Nov; 14 Suppl H():30-5. PubMed ID: 7904936
[TBL] [Abstract][Full Text] [Related]
13. Proarrhythmia with class III antiarrhythmic drugs: types, risks, and management.
Hohnloser SH
Am J Cardiol; 1997 Oct; 80(8A):82G-89G. PubMed ID: 9354415
[TBL] [Abstract][Full Text] [Related]
14. The effects of beta-adrenergic stimulation on the frequency-dependent electrophysiologic actions of amiodarone and sematilide in humans.
Sager PT; Follmer C; Uppal P; Pruitt C; Godfrey R
Circulation; 1994 Oct; 90(4):1811-9. PubMed ID: 7923666
[TBL] [Abstract][Full Text] [Related]
15. Monotherapy versus combination therapy with class III antiarrhythmic agents to attenuate transmural dispersion of repolarization: a potential risk factor for torsade de pointes.
Shah SA; Kluger J; White CM
Pharmacotherapy; 2007 Sep; 27(9):1297-305. PubMed ID: 17723083
[TBL] [Abstract][Full Text] [Related]
16. A new mechanism preventing proarrhythmia in chronic heart failure: rapid phase-III repolarization explains the low proarrhythmic potential of amiodarone in contrast to sotalol in a model of pacing-induced heart failure.
Frommeyer G; Milberg P; Witte P; Stypmann J; Koopmann M; Lücke M; Osada N; Breithardt G; Fehr M; Eckardt L
Eur J Heart Fail; 2011 Oct; 13(10):1060-9. PubMed ID: 21873342
[TBL] [Abstract][Full Text] [Related]
17. Symposium on the management of ventricular dysrhythmias. Antifibrillatory versus antiectopic therapy.
Anderson JL
Am J Cardiol; 1984 Jul; 54(2):7A-13A. PubMed ID: 6147079
[TBL] [Abstract][Full Text] [Related]
18. Effects of chronic treatment by amiodarone on transmural heterogeneity of canine ventricular repolarization in vivo: interactions with acute sotalol.
Merot J; Charpentier F; Poirier JM; Coutris G; Weissenburger J
Cardiovasc Res; 1999 Nov; 44(2):303-14. PubMed ID: 10690307
[TBL] [Abstract][Full Text] [Related]
19. Reduction of dispersion of repolarization and prolongation of postrepolarization refractoriness explain the antiarrhythmic effects of quinidine in a model of short QT syndrome.
Milberg P; Tegelkamp R; Osada N; Schimpf R; Wolpert C; Breithardt G; Borggrefe M; Eckardt L
J Cardiovasc Electrophysiol; 2007 Jun; 18(6):658-64. PubMed ID: 17521304
[TBL] [Abstract][Full Text] [Related]
20. New class III antiarrhythmic drugs.
Katritsis D; Camm AJ
Eur Heart J; 1993 Nov; 14 Suppl H():93-9. PubMed ID: 8293759
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
